The pre-seed round was led by Creator Fund and will support the development of B2B construction information management products.
"Our mission at Didimi is to transform the way information is exchanged and managed across construction stakeholders. When architects and engineers exchange models in the current format, huge information loss occurs due to the fundamental interoperability problems in the industry, leading to time waste and mistakes. The Didimi platform is our ambitious answer to this problem. We are extremely grateful to have found the right investors that can back us in this vision and help us change these antiquated practices in the industry."
The seed round was led by Khosla Ventures with participation from Entrepreneur First and angel investors.
"At GOSH, we’re committed to rigorously trialling the best new clinical technologies to generate valuable data and evaluate their impact. We’re very excited to have this opportunity to partner with TORTUS and to study how generative AI tools could help our clinicians by safely freeing them from administrative tasks and allowing them to spend more time directly interacting with patients."
The London fintech firm raised the capital from backers including Bain Capital and Unusual Ventures to satisfy tier-one regulatory requirements.
"International payments are a pain point across a range of industries including e-commerce, marketplaces, and online platforms such as payroll and pensions to name just a few. These are sectors that need to cater for complex layers of incoming and outgoing payments, to and from large volumes of businesses and individuals, and across multiple jurisdictions. Getting the licences in Ireland and the UK sets us up wonderfully for 2024 and means that international businesses can now use our solution to remove these headaches in a regulated environment."
The funding extension was backed by new investor We Venture Capital alongside returning backers Nina Capital, Apex Ventures, and Cambridge Enterprise to prepare the firm for Series A.
"Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus."
